A First-in-human Study of IMP1734 in Participants With Advanced Solid Tumors
Phase 1/2
70
about 3 years
18–89
23 sites in AR, AZ, CA +13
Why this study is shown
What this study is about
Researchers are testing a new medication called IMP1734 to see if it can help people with advanced solid tumors. The trial will last for about 1086 days and involve approximately 70 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take IMP1734
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of subjects with adverse events, treatment emergent adverse events or serious adverse events
Secondary: Overall Response Rate, Pharmacokinetic parameters of IMP1734
Oncology